The Zacks Analyst Blog Highlights HSBC, Abbott, Shell and Oak Valley

05.12.25 12:12 Uhr

Werte in diesem Artikel
Aktien

107,26 EUR 0,58 EUR 0,54%

12,32 EUR -0,08 EUR -0,65%

31,64 EUR -0,24 EUR -0,74%

Indizes

950,0 PKT 2,2 PKT 0,23%

2.945,9 PKT 0,0 PKT 0,00%

PKT PKT

1.714,2 PKT 5,1 PKT 0,30%

9.716,3 PKT 5,4 PKT 0,06%

5.238,9 PKT 4,6 PKT 0,09%

25.935,9 PKT 175,2 PKT 0,68%

23.505,1 PKT 51,0 PKT 0,22%

3.519,6 PKT -17,6 PKT -0,50%

9.496,0 PKT 21,0 PKT 0,22%

18.190,5 PKT 4,6 PKT 0,03%

3.442,4 PKT 3,3 PKT 0,09%

6.857,1 PKT 7,4 PKT 0,11%

4.832,0 PKT 11,9 PKT 0,25%

For Immediate ReleaseChicago, IL – December 5, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: HSBC Holdings plc HSBC, Abbott Laboratories ABT, Shell plc SHEL and Oak Valley Bancorp OVLY.Here are highlights from Thursday’s Analyst Blog:Top Analyst Reports HSBC, Abbott and ShellThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including HSBC Holdings plc (HSBC), Abbott Laboratories (ABT) and Shell plc (SHEL), as well as a micro-cap stock Oak Valley Bancorp (OVLY). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Jobless Claims Puzzlingly Light, Lowest in 3 YearsToday's Featured Research ReportsHSBC's shares have outperformed the Zacks Banks - Foreign industry over the past year (+60.2% vs. +51.2%). The company's stock performance reflects strong shareholder returns and the success of its Asia pivot strategy despite macroeconomic headwinds. A robust capital position and an expansive global footprint will support financials.As part of its focus on optimizing returns, the company is divesting operations in underperforming regions and has exited retail banking across multiple markets. Though these moves position it for improved operating efficiency, they are likely to temporarily weigh on revenue growth.This, along with subdued loan demand, presents a near-term woe. Elevated costs tied to efforts to expand market share will hurt profits. Yet, business simplification and restructuring initiatives will fuel long-term growth. HSBC's partnership with Mistral AI is in sync with its restructuring plan and will help improve efficiency.(You can read the full research report on HSBC here >>>)Shares of Abbott have outperformed the Zacks Medical - Products industry over the past year (+10.1% vs. -0.7%). The company's strong pipeline continues to open up new opportunities, supporting its 2025 outlook. The Medical Devices arm remains a key growth driver, led by the FreeStyle Libre CGM franchise, including the upcoming dual-analyte sensor integrating glucose and ketone monitoring.In Diagnostics, Abbott's Alinity platforms and Point of Care tests are driving growth outside China, even as VBP-related pricing and volume pressures continue to create a drag. Abbott remains optimistic about its biosimilar strategy, which is expected to boost EPD sales. Within Nutrition, Abbott gains traction, driven by a strong Adult Nutrition and innovation across Ensure and Glucerna brands.Yet, persistent challenges in the Diagnostics, along with tariff impacts, FX fluctuations, and macroeconomic headwinds, continue to weigh modestly on overall growth.(You can read the full research report on Abbott here >>>)Shell's shares have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+21.9% vs. +10.6%). This London-based oil supermajor looks fairly balanced at the moment. The company's third quarter 2025 results highlight resilience and disciplined execution across its portfolio.Strong LNG performance, robust upstream output from projects like Whale and Mero showcase solid cash generation and shareholder commitment. Strategic divestments and targeted reinvestments underscore capital discipline and support long-term transition goals.However, revenue decline alongside rising operating costs is pressuring margins. Chemical and product earnings plunged 65%, revealing downstream weakness, and renewables remain minimally profitable. With stable fundamentals offset by cyclical and structural headwinds, a neutral stance is justified—balancing solid financial health against uneven growth and energy-transition uncertainty.(You can read the full research report on Shell here >>>)Shares of Oak Valley have underperformed the Zacks Banks - West industry over the past year (-6.4% vs. -5%). This microcap company with market capitalization of $235.54 million is witnessing headwinds which include margin pressure from rising deposit costs, a 10% jump in non-interest expenses, and sluggish 0.6% loan growth. CRE loans account for 87% of the portfolio, exposing the bank to sector-specific risk. Additionally, $32.4 million in unrealized securities losses have weighed on book value.Nevertheless, Oak Valley Bancorp posted strong liquidity growth in 2025, with cash surging 46.5% to $247.2 million, supported by 4.7% deposit growth and a 5% rise in total assets. Credit quality remains pristine, with zero non-accrual loans and minimal charge-offs, reflecting disciplined underwriting.Strategic expansion into Downtown Lodi boosts regional market presence and supports long-term growth. Dividend payouts rose 33% year over year, underlining a shareholder-friendly capital approach.(You can read the full research report on Oak Valley here >>>)Free: Instant Access to Zacks' Market-Crushing StrategiesSince 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.Get all the details here >>Media ContactZacks Investment Research800-767-3771 ext. 9339support@zacks.com                                      https://www.zacks.com                                                 Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT): Free Stock Analysis Report HSBC Holdings plc (HSBC): Free Stock Analysis Report Oak Valley Bancorp (CA) (OVLY): Get Free Report Shell PLC Unsponsored ADR (SHEL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Abbott Laboratories und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Abbott Laboratories

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Abbott Laboratories

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Shell (ex Royal Dutch Shell)

Wer­bung

Analysen zu Shell (ex Royal Dutch Shell)

DatumRatingAnalyst
08:51Shell (ex Royal Dutch Shell) OverweightJP Morgan Chase & Co.
26.11.2025Shell (ex Royal Dutch Shell) NeutralUBS AG
03.11.2025Shell (ex Royal Dutch Shell) BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
31.10.2025Shell (ex Royal Dutch Shell) BuyUBS AG
31.10.2025Shell (ex Royal Dutch Shell) BuyGoldman Sachs Group Inc.
DatumRatingAnalyst
08:51Shell (ex Royal Dutch Shell) OverweightJP Morgan Chase & Co.
03.11.2025Shell (ex Royal Dutch Shell) BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
31.10.2025Shell (ex Royal Dutch Shell) BuyUBS AG
31.10.2025Shell (ex Royal Dutch Shell) BuyGoldman Sachs Group Inc.
31.10.2025Shell (ex Royal Dutch Shell) OverweightJP Morgan Chase & Co.
DatumRatingAnalyst
26.08.2020Shell (Royal Dutch Shell) (A) UnderweightBarclays Capital
29.11.2017Shell B SellCitigroup Corp.
29.11.2017Shell (Royal Dutch Shell) (A) SellCitigroup Corp.
29.11.2017Shell B SellCitigroup Corp.
30.01.2015Royal Dutch Shell Grou b SellS&P Capital IQ

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Shell (ex Royal Dutch Shell) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen